Author:
Agarwala Sanjiv S.,Middleton Mark R.,Atkins Michael B.
Publisher
Springer International Publishing
Reference141 articles.
1. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J (1994) Docetaxel (taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 30a:1061–1064
2. Agarwala SS, Kirkwood JM (2003) Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer 97:121–127
3. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22:2101–2107
4. Agarwala SS, Tarhini A, Kirkwood JM, Cai C, Stover L, Moschos S, Gooding W (2006) Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HDB) Il-2 in patients with metastatic melanoma. Am J Clin Oncol 24:462s
5. Ahmann DL, Hahn RG, Bisel HF (1974) Evaluation of 1-(2-chloroethyl-3-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45338) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma. Cancer 33:615–618